Evidence Based QUality Improvement for Prescribing Stewardship in ICU (EQUIPS-ICU)

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 years and older
• All sexes
• Healthy volunteers accepted
• Adult, Older adult

Study population: All adult ICUs within CCAA-affiliated CQRs, where surveillance of antimicrobial utilisation has already been established will be considered for participation. ICUs must appoint a named Champion in order to participate. A survey will be conducted to determine pre-existing prescribing practice and the presence, characteristics and current adoption of structured review activities. Pre-existing antimicrobial review processes are neither a requirement for an ICU to participate nor an exclusion criterion. Instead, parallel to the survey, pre-implementation patient-level data pertaining to current antimicrobial prescribing review practices will be measured during months 1-2. ICU's which are found to already have a structured antimicrobial review in place, and which demonstrate adoption and reach of 80% or greater (median over the 2 months) will not be eligible to participate in the implementation to reduce confounding of the selected measures for implementation success.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Evidence Based QUality Improvement for Prescribing Stewardship in ICU: Can a Structured Antimicrobial Review be Implemented in LMIC ICUs?

Conditions

Antimicrobial Stewardship

Being tested

Structured antimicrobial review

Keywords

Critical care, Antimicrobial Stewardship, Implementation, Quality improvement, Low or Middle Income Country (LMIC)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• Structured antimicrobial reviewBehavioural

  The appropriateness of the documented indication, route of administration, expected duration and stop date of all antimicrobials will be reviewed within 48 hours of their prescription.

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Fidelity

   The proportion of prescriptions reviewed as intended (reviewed within 48hours with documentation of all 4 review components: indication, route, duration, stop date). Reported as a proportion of the number of possible reviews.

   Measured: Evaluated over calendar month periods during months 4-6 (i.e. the three months immediately following implementation)

2. Reach

   Proportion of eligible patients who receive a review

   Measured: Evaluated over calendar month periods during months 4-6 (i.e. the three months immediately following implementation)

3. Adoption

   Proportion of prescriptions reviewed as intended once implementation support has been withdrawn

   Measured: Evaluated over the calendar month period of month 7

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted31 Oct 2024
2. Study start13 Jan 2025
3. Primary completion31 Dec 2026 (estimated)
4. Study completion31 Dec 2026 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Publications (1)Papers the sponsor has linked to this study.
• Other trials for Antimicrobial StewardshipStudies of the same condition, open and under way.
• More trials run by University of OxfordThe sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.